Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Thrombopoietin inhibition abrogates JAK2V617F clonal expansion in a murine model of myeloproliferative neoplasm

View Full Paper
Ask AI
Bookmark
Share

Authors

CLChristina U. Lorentz

Discussion

Loading...

Member takes

Overview

Observational analysis reveals JAK2V617F clonal expansion is significantly reduced by targeting TPO in murine myeloproliferative neoplasms, suggesting a novel therapeutic approach.

Key Points

  • JAK2V617F clonal expansion was reduced by 44% with Thpo antisense oligonucleotide treatment in mice.
  • In a transplant model, ruxolitinib treatment increased plasma TPO levels by 71%, unlike Thpo antisense oligonucleotide.
  • Assessment using a murine myeloproliferative neoplasm model demonstrated consistent effects on blood counts and spleen size.
  • Targeting TPO may complement JAK2 inhibition, highlighting the need for further investigation in MPN therapies.

Cite This Study

Christina U. Lorentz (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd65https://doi.org/10.1182/blood-2025-1987
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Selective ASO-based JAK2 inhibitor for the treatment of hematological malignancies with JAK2 V617F mutation burden2025
  2. 2Single-cell transcriptomic studies reveal altered heterogeneity in CD41 enriched megakaryocytes after targeted therapy in myeloproliferative neoplasm2025
  3. 3Direct small molecule inhibition of RAS enhances JAK2 inhibitor therapy in preclinical models of myeloproliferative neoplasms2025
  4. 4The anti-MPL antibody AMM2 prevents cardiovascular dysfunction in a mouse model of myeloproliferative neoplasms2025
  5. 5Recombinant human thrombopoietin improves hematopoietic stem cell differentiation and T-cell immune homeostasis in patients with severe aplastic anemia by upregulating c-MPL2025